eligibility_summary
Eligible: age 1–25 with refractory/recurrent B‑ALL expressing CD19/20/22, life expectancy ≥8 wks, weight ≥10 kg. Procurement: recovery plus washouts, exclude other active cancer, severe infection (HIV/HBV/HCV/HTLV), primary immunodeficiency, pregnancy/breastfeeding. T‑cell therapy: defined R/R ALL (incl post‑allo‑HCT), CAR+ cells ≥15%, adequate liver/renal/cardiac, O2 ≥90%, performance ≥50%, washouts. Exclude pregnancy, prohibitive illness, active GVHD/immunosuppression, acute CNS disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: TRICAR-ALL, an autologous gene‑modified T‑cell therapy. Patient T cells are retrovirally transduced to co‑express three antibody‑derived CARs targeting CD19, CD20, and CD22, each with 4‑1BB (CD137) costimulation and CD3ζ signaling to boost activation, proliferation, persistence, and cytotoxicity. Lymphodepletion: cyclophosphamide (alkylating DNA crosslinker) and fludarabine (purine analog antimetabolite) to deplete host lymphocytes and enhance CAR-T expansion. Mechanism/targets: CAR engagement of CD19/20/22 on B‑lineage leukemic cells triggers T‑cell killing (perforin/granzyme, cytokines) and aims to reduce antigen‑escape by multi‑antigen targeting. Pathways engaged: CAR‑CD3ζ TCR signaling and 4‑1BB pro‑survival/NF‑κB signaling in T cells, depletion of endogenous lymphocytes by Cy/Flu.